RE:The Only Clock I'm Punching Is Algernon's Right In The Face. Follow up post:
Ifenprodil for IPF and Chronic Cough has always been Algernon's strongest drug candidate since its purchase from Nash Pharmaceuticals back in 2018. It was considered to be 10% of the total value of the purchase not including handing over 50% of Algernon to Nash Pharmaceuticals in the reverse takeover. followed up with massive dilution. Now the company has come to another critical cross road of decision making with any/all monies from this latest dilution plans across North America. Will they continue to make Chronic Cough just another "thing" they are pursuing while the CEO jumps up and down screaming to the market about its DMT angle? Have we not learned that the Hot Topic - Flavor Of The Year - drug pursuits by the sector proves Only Fools Rush In? If anything, Algernon needs to go All In on Chronic Cough versus how they went after COVID-19 instead. Don 't make DMT the topline story for Algernon. Algernon is in a field of psychedelic competitors that will run circles around Algernon's narrative. They could care less about DMT Stroke being the “World's First” DMT Stroke program. The psych fanatics/culture is more akin to the marijuana sector types. They don’t get too far into the weeds beyond mind altered states. The Stroke program sounds too complicated for most of your target audience. They just want what they consider safe and awesomely super cool pain relievers that are FDA approved. IMO, the DMT stroke program is either pure genius or pure insanity. I remain on the fence as to which it is but I’m rooting for the genius. However, before getting to any of those very long term brain surgery answers, I'd go after the most obvious and simple path to success here. The Chronic Cough market has proven they want a product. There's nobody standing in the way of Algernon creating its own successful narrative without having to resort to an incredible level of jumping up and down trying to get attention in the psych sector. We don't need to see the CEO's face every week in a new webcast going around in circles over DMT. We need a fast, surgical and methodical approach to fast tracking a Phase 2 Chronic Cough clinical trial in North America. Against the backdrop of Global Recession, War with Russia and likely China before it's over, new waves of Global Pandemics (Monkey Pox etc etc), the time to go All In with your #1 drug candidate is NOW. Follow the money! It's not rocket science but it could propel the Market Cap like a rocket.
Serenade to Gold Standard Chronic Cough study in North America